2017 American Transplant Congress
Renal Transplant Recipients with Indication for Antiplatelet Therapy: Increased Risk for the Allograft?
General Visceral and Transplantation Surgery, University Hospital, Essen, Germany
Background Antiplatelet therapy is common in patients on the waiting list for kidney transplantation increasing the risk for perioperative blood loss. This study evaluates the…2017 American Transplant Congress
Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.
Acute rejection rates and short-term graft survival have improved substantially as a result of advances in immunosuppression (IS), though longer-term graft survival rates have improved…2017 American Transplant Congress
Shared Decision Aid to Decipher Long-Term Treatment Risks for End Stage Renal Disease Patients.
Kidney transplantation is the preferred treatment for end stage renal disease (ESRD) compared to dialysis. The incidence of ESRD continues to increase while the gap…2017 American Transplant Congress
De Novo Low-Dose Sirolimus versus Mycophenolate Mofetil in Combination with Extended-Release Tacrolimus in Kidney Transplant Recipients.
Previous studies reported that tacrolimus (TAC) with high-dose sirolimus (SRL) was associated with worse outcomes in kidney transplantation, compared to TAC with mycophenolate mofetil (MMF.).…2017 American Transplant Congress
Differential Effects of the Novel ATP-Competitive mTOR Inhibitor (TORKinib) AZD2014 and Rapamycin on Alloimmunity and Transplant Survival.
Surgery, Thomas Starzl Transplantation Institute, Pittsburgh, PA
Background: Rapamycin (RAPA), is an immunosuppressive agent that inhibits the mechanistic target of Rapamycin (mTOR), the kinase subunit of two mTOR- containing complexes (mTORC1 and…2017 American Transplant Congress
Improved Outcome of Kidney Transplants by Donor Recipient Matching Based on Predicted Indirectly Recognizable HLA Epitopes.
Introduction: De novo donor-specific HLA antibodies (dnDSA) are recognized as a risk factor for graft loss. Determinants of DSA specificity are generated via the indirect…2017 American Transplant Congress
Not All Cellular Rejections Are the Same: Differences in Early and Late Hepatic Allograft Rejection.
While acute cellular rejection (ACR) after liver transplantation (LT) is not thought to cause long-term graft injury and inferior outcomes, this notion has been challenged…2017 American Transplant Congress
Variations in Risk-Appetite Between UK Kidney Transplant Centres and Impact on Patient and Graft Outcomes.
Introduction: Risks associated with deceased donors may be donor-related, organ-related, or both. Variations between transplant centres in the risks they are prepared to accept ('risk…2017 American Transplant Congress
Poor Outcome of Polyomavirus -Associated Nephropathy with Glomerular Parietal Epithelial Cells Infected by Polyomavirus.
Background: Bowman's capsular epithelium infected by polyomavirus(Py) in polyomavirus -associated nephropathy (PyVAN) is infrequent and considered as the advanced stage of the disease. The aim…2017 American Transplant Congress
C1q+ and IgG3+ De Novo Donor Specific Antibody Are Associated with Allograft Failure in a Multicenter Cohort.
Introduction: De novo donor specific antibody (dnDSA) is a risk factor for antibody mediated rejection and allograft loss, but dnDSA does not always lead to…
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 113
- Next Page »